{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:37:11Z","timestamp":1792103831128,"version":"4.4.0"},"reference-count":31,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T00:00:00Z","timestamp":1726876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: The concurrent presence of chronic hepatitis B virus (CHB) infection and metabolic dysfunction-associated steatotic liver disease (MASLD) presents a unique clinical scenario with implications that are not yet fully understood. This study aims to characterize the distinct clinical and virological features of CHB in the context of MASLD and evaluate its impact on disease progression and outcomes. Methods: Utilizing a comprehensive health maintenance organization database, this study included 1186 patients with CHB from 2000\u20132020. Patients were categorized into two groups: CHB-MASLD (n = 188) and CHB alone (n = 998). CHB diagnosis was confirmed by serological markers, while MASLD was diagnosed based on imaging and cardiometabolic risk factors. Comparative analysis and multiple regression models were applied to assess variables related to viral parameters and clinical outcomes. Results: The CHB-MASLD group was older (mean age of 45.2 vs. 39.1, p &lt; 0.001) with higher rates of obesity (46.8% vs. 23.8%, p &lt; 0.001), diabetes (36.2% vs. 17.3%, p &lt; 0.001), and dyslipidemia. Distinct viral profiles included higher HBeAg negativity (96.2%), a higher rate of HBeAg-negative infection (70.4% vs. 63.8%; p &lt; 0.001), and increased HBeAg seroconversion under treatment. Cirrhosis was more prevalent in the CHB-MASLD group (9.6% vs. 4.4%, p = 0.007), while HCC rates were comparable. Multivariate analysis identified age, male gender, chronic active hepatitis, and diabetes as predictors of cirrhosis. Conclusions: CHB-MASLD patients were distinguished by a higher prevalence of metabolic features, along with a distinct viral profile marked by increased chronic HBeAg infection, higher rates of HBeAg seroconversion, and a potential association with worse disease outcomes.<\/jats:p>","DOI":"10.3390\/jcm13185608","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T08:56:06Z","timestamp":1727168166000},"page":"5608","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Characterizing Unique Clinical and Virological Profiles in Concurrent Chronic Hepatitis B and Metabolic Dysfunction-Associated Liver Disease: Insights from a Population-Based Cohort Study"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5428-7180","authenticated-orcid":false,"given":"Fadi","family":"Abu Baker","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Hillel Yaffe Medical Center, Technion Faculty of Medicine, Hadera 38100, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdel-Rauf","family":"Zeina","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Hillel Yaffe Medical Center, Technion Faculty of Medicine, Hadera 38100, Israel"},{"name":"Department of Radiology, Hillel Yaffe Medical Center, Technion Faculty of Medicine, Hadera 38100, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randa","family":"Taher","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Hillel Yaffe Medical Center, Technion Faculty of Medicine, Hadera 38100, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saif","family":"Abu Mouch","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hillel Yaffe Medical Center, Technion Faculty of Medicine, Hadera 38100, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4389-8896","authenticated-orcid":false,"given":"Ariel","family":"Israel","sequence":"additional","affiliation":[{"name":"Research Institute\u2014Leumit Health Services, Tel-Aviv 6274411, Israel"},{"name":"Department of Epidemiology and Preventive Medicine, School of Public Health, Faculty of Medical & Health Sciences, Tel-Aviv University, Tel-Aviv 6274411, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,21]]},"reference":[{"key":"ref_1","unstructured":"GBD 2019 Hepatitis B Collaborators (2022). Global, regional, and national burden of hepatitis B, 1990\u20132019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol. Hepatol., 7, 796\u2013829."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jhep.2020.09.013","article-title":"A global investment framework for the elimination of hepatitis B","volume":"74","author":"Howell","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7570\/jomes23052","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review","volume":"32","author":"Chan","year":"2023","journal-title":"J. Obes. Metab. Syndr."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3748\/wjg.v28.i3.310","article-title":"Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link","volume":"28","author":"Chrysavgis","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1001\/jama.2018.3795","article-title":"Chronic Hepatitis B Infection: A Review","volume":"319","author":"Tang","year":"2018","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.3748\/wjg.v27.i26.3971","article-title":"Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion","volume":"27","author":"Shi","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"107295","DOI":"10.18632\/oncotarget.22364","article-title":"Hepatitis B virus infection and the risk of nonalcoholic fatty liver disease: A meta-analysis","volume":"8","author":"Xiong","year":"2017","journal-title":"Oncotarget"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/sj.ijo.0803204","article-title":"A population-based study investigating the association between metabolic syndrome and hepatitis B\/C infection (Keelung Community-based Integrated Screening study No. 10)","volume":"30","author":"Jan","year":"2006","journal-title":"Int. J. Obes."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3748\/wjg.v22.i1.155","article-title":"Association between hepatitis B and metabolic syndrome: Current state of the art","volume":"22","author":"Jarcuska","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10620-012-2343-9","article-title":"Clinical and virological characteristics post HBsAgseroclearance in hepatitis B virus carriers with hepatic steatosis versus those without","volume":"58","author":"Chu","year":"2013","journal-title":"Dig. Dis. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e27909","DOI":"10.5812\/hepatmon.15(5)2015.27909","article-title":"Saturated fatty acid inhibits viral replication in chronic hepatitis B virus infection with nonalcoholic fatty liver disease by toll-like receptor 4-mediated innate immune response","volume":"15","author":"Zhang","year":"2015","journal-title":"Hepat. Mon."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e13113","DOI":"10.1016\/j.heliyon.2023.e13113","article-title":"Hepatitis B virus infection combined with nonalcoholic fatty liver disease: Interaction and prognosis","volume":"9","author":"Liu","year":"2023","journal-title":"Heliyon"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1111\/liv.15252","article-title":"Impact of NAFLD on the outcome of patients with chronic hepatitis B in Asia","volume":"42","author":"Yang","year":"2022","journal-title":"Liver Int."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Tourkochristou, E., Assimakopoulos, S.F., Thomopoulos, K., Marangos, M., and Triantos, C. (2022). NAFLD and HBV interplay-related mechanisms underlying liver disease progression. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.965548"},{"key":"ref_16","unstructured":"European Association for the Study of the Liver (2017). European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol., 67, 370\u2013398."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/jmv.25621","article-title":"The impact of hepatitis B virus infection status on the prevalence of nonalcoholic fatty liver disease: A population-based study","volume":"92","author":"Huang","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.clinre.2020.06.009","article-title":"Concurrence of HBV infection and non-alcoholic fatty liver disease is associated with higher prevalence of chronic kidney disease","volume":"45","author":"Lin","year":"2021","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.jhep.2014.05.045","article-title":"Prevalence and causes of elevated serum aminotransferase levels in a population-based cohort of persons with chronic hepatitis B virus infection","volume":"61","author":"Spradling","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/liv.13933","article-title":"Hepatitis b virus infection and risk of non-alcoholic fatty liver disease: A population-based cohort study","volume":"39","author":"Zhu","year":"2019","journal-title":"Liver Int."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41575-018-0009-6","article-title":"Triggering and resolution of inflammation in NASH","volume":"15","author":"Schuster","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","article-title":"Global incidence and prevalence of nonalcoholic fatty liver disease","volume":"29","author":"Teng","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jhepr.2019.02.002","article-title":"Liver steatosis is a strong predictor of mortality and cancer in chronic hepatitis B regardless of viral load","volume":"1","author":"Peleg","year":"2019","journal-title":"JHEP Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/hep.28917","article-title":"Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: A cohort study","volume":"65","author":"Joo","year":"2017","journal-title":"Hepatology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s12072-018-9877-7","article-title":"Non-alcoholic hepatic steatosis attenuates hepatitis B virus replication in an HBV-immunocompetent mouse model","volume":"12","author":"Hu","year":"2018","journal-title":"Hepatol. Int."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1093\/infdis\/jiab241","article-title":"Incidences determinants of functional cure during entecavir or tenofovirdisoproxil fumarate for chronic hepatitis B","volume":"224","author":"Hsu","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Jin, X., Chen, Y.P., Yang, Y.D., Li, Y.M., Zheng, L., and Xu, C.Q. (2012). Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0034198"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3350\/cmh.2018.0054","article-title":"Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir","volume":"25","author":"Kim","year":"2019","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/j.1478-3231.2009.01976.x","article-title":"Hepatic steatosis and fibrosis in young men with treatment-na\u00efve chronic hepatitis B","volume":"29","author":"Yun","year":"2009","journal-title":"Liver Int."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejim.2014.12.001","article-title":"Prevalence of steatosis insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis, C and non-alcoholic fatty liver disease","volume":"26","author":"Pais","year":"2015","journal-title":"Eur. J. Intern. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/jvh.13594","article-title":"No influence of hepatic steatosis on the 3-year outcomes of patients with quiescent chronic hepatitis B","volume":"28","author":"Chang","year":"2021","journal-title":"J. Viral Hepat."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/18\/5608\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:01:47Z","timestamp":1760112107000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/18\/5608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,21]]},"references-count":31,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["jcm13185608"],"URL":"https:\/\/doi.org\/10.3390\/jcm13185608","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,21]]}}}